Waltham, MA, United States
Waltham, MA, United States

Time filter

Source Type

Kluge A.F.,Avila Therapeutics | Petter R.C.,Avila Therapeutics
Current Opinion in Chemical Biology | Year: 2010

Structural modification of naturally occurring β-lactams and β-lactones is a highly effective strategy for generating drugs for treating bacterial infections, cancer, obesity, and hyperlipidemia. These drugs acylate catalytic amino acids (serine, threonine, or cysteine) in enzyme targets such as penicillin-binding proteins (PBPs), β-lactamases, lipases, HMG-CoA reductase, fatty acid synthetase, and the 20S proteasome. Optimally performing drugs combine features of high target affinity, chemoselective reactivity, and high stability of the acylated target protein. This review provides a perspective on these two classes of acylating agents and summarizes recent advances in mechanism and structure-based design of acylating drugs. © 2010 Elsevier Ltd. All rights reserved.


Patent
Avila Therapeutics | Date: 2011-10-31

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.


Patent
Avila Therapeutics | Date: 2011-10-31

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.


Patent
Avila Therapeutics | Date: 2012-04-10

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.


Patent
Avila Therapeutics | Date: 2012-03-08

The present invention provides compounds, compositions thereof, and methods of using the same.


Patent
Avila Therapeutics | Date: 2011-11-08

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.


Patent
Avila Therapeutics | Date: 2011-02-01

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.


Patent
Avila Therapeutics | Date: 2011-02-01

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.


Patent
Avila Therapeutics | Date: 2012-05-31

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.


Patent
Avila Therapeutics | Date: 2011-08-08

The present invention provides a salt form, and compositions thereof, useful as an inhibitor of one or more protein kinases and which exhibits desirable characteristics for the same.

Loading Avila Therapeutics collaborators
Loading Avila Therapeutics collaborators